清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Photodynamic Therapy—Current Limitations and Novel Approaches

光动力疗法 光敏剂 血卟啉 单线态氧 癌症治疗 医学 癌症 癌症治疗 恶性细胞 化学 内科学 有机化学 氧气
作者
Gürcan Günaydın,Mustafa Emre Gedik,Seylan Ayan
出处
期刊:Frontiers in Chemistry [Frontiers Media SA]
卷期号:9 被引量:315
标识
DOI:10.3389/fchem.2021.691697
摘要

Photodynamic therapy (PDT) mostly relies on the generation of singlet oxygen, via the excitation of a photosensitizer, so that target tumor cells can be destroyed. PDT can be applied in the settings of several malignant diseases. In fact, the earliest preclinical applications date back to 1900’s. Dougherty reported the treatment of skin tumors by PDT in 1978. Several further studies around 1980 demonstrated the effectiveness of PDT. Thus, the technique has attracted the attention of numerous researchers since then. Hematoporphyrin derivative received the FDA approval as a clinical application of PDT in 1995. We have indeed witnessed a considerable progress in the field over the last century. Given the fact that PDT has a favorable adverse event profile and can enhance anti-tumor immune responses as well as demonstrating minimally invasive characteristics, it is disappointing that PDT is not broadly utilized in the clinical setting for the treatment of malignant and/or non-malignant diseases. Several issues still hinder the development of PDT, such as those related with light, tissue oxygenation and inherent properties of the photosensitizers. Various photosensitizers have been designed/synthesized in order to overcome the limitations. In this Review, we provide a general overview of the mechanisms of action in terms of PDT in cancer, including the effects on immune system and vasculature as well as mechanisms related with tumor cell destruction. We will also briefly mention the application of PDT for non-malignant diseases. The current limitations of PDT utilization in cancer will be reviewed, since identifying problems associated with design/synthesis of photosensitizers as well as application of light and tissue oxygenation might pave the way for more effective PDT approaches. Furthermore, novel promising approaches to improve outcome in PDT such as selectivity, bioengineering, subcellular/organelle targeting, etc. will also be discussed in detail, since the potential of pioneering and exceptional approaches that aim to overcome the limitations and reveal the full potential of PDT in terms of clinical translation are undoubtedly exciting. A better understanding of novel concepts in the field ( e.g. enhanced, two-stage, fractional PDT) will most likely prove to be very useful for pursuing and improving effective PDT strategies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
华仔应助去去去去采纳,获得30
2秒前
3秒前
38秒前
去去去去发布了新的文献求助30
44秒前
方琼燕完成签到 ,获得积分10
1分钟前
段誉完成签到 ,获得积分10
1分钟前
yanhua完成签到,获得积分20
1分钟前
1分钟前
桐桐应助Mine采纳,获得10
1分钟前
1分钟前
1分钟前
Mine发布了新的文献求助10
1分钟前
2分钟前
Ava应助Mine采纳,获得50
2分钟前
晶杰发布了新的文献求助10
3分钟前
hongxuezhi完成签到,获得积分10
3分钟前
4分钟前
Mine发布了新的文献求助50
4分钟前
晶杰完成签到 ,获得积分10
4分钟前
大个应助雅樱采纳,获得10
4分钟前
Hello应助要减肥的婷冉采纳,获得10
5分钟前
要减肥的婷冉完成签到,获得积分10
5分钟前
5分钟前
Mine完成签到,获得积分10
5分钟前
5分钟前
7分钟前
8分钟前
jyy应助FUNG采纳,获得10
8分钟前
8分钟前
慧喆完成签到 ,获得积分10
8分钟前
刘佳佳完成签到 ,获得积分10
8分钟前
YANGLan完成签到,获得积分10
9分钟前
赘婿应助科研通管家采纳,获得10
10分钟前
迷茫的一代完成签到,获得积分10
10分钟前
FUNG发布了新的文献求助10
10分钟前
肆肆完成签到,获得积分10
11分钟前
Tei完成签到,获得积分10
11分钟前
xaopng完成签到,获得积分10
11分钟前
小西完成签到 ,获得积分10
11分钟前
Anan完成签到,获得积分10
13分钟前
高分求助中
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
宽禁带半导体紫外光电探测器 388
Case Research: The Case Writing Process 300
Global Geological Record of Lake Basins 300
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3142742
求助须知:如何正确求助?哪些是违规求助? 2793633
关于积分的说明 7807045
捐赠科研通 2449892
什么是DOI,文献DOI怎么找? 1303518
科研通“疑难数据库(出版商)”最低求助积分说明 626959
版权声明 601335